Drug Trial Radar · NCT06780670
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
443
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Jun 27, 2028
Study completion Jul 19, 2033
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment
Conditions
- Prostate Cancer
Interventions
Investigators choice of SoCDrug
The control treatment in Phase III is investigator's choice of SoC
AAA817Drug
The investigational treatment is AAA817
AAA817Drug
The investigational treatment is AAA817
AAA817Drug
Investigational treatment is the Dose B of AAA817
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biochemical response rate (Phase II)Time frame: from date of randomization up to approximately 24 months
- Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase IITime frame: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later
- Tolerability of the proposed dose of AAA817- Phase IITime frame: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817
- Radiographic progression-free survival (rPFS)- Phase IIITime frame: from date of randomization up to approximately 24 months
- Overall survival (OS)- Phase IIITime frame: from date of randomization up to approximately 24 months
Locations
93 sites in 13 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona · Recruiting
VA Greater LA Healthcare System
Los Angeles, California · Recruiting
VA Palo Alto Health Care System
Palo Alto, California · Recruiting
Stanford University Medical Center
Palo Alto, California · Recruiting
Sansum Clinic
Santa Barbara, California · Recruiting
Saint Johns Cancer Institute
Santa Monica, California · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Hartford Hospital
Hartford, Connecticut · Recruiting
Baptist Health South
Miami, Florida · Recruiting
AdventHealth
Orlando, Florida · Recruiting
University Cancer and Blood Center LLC
Athens, Georgia · Recruiting
Emory University
Atlanta, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Indiana University
Indianapolis, Indiana · Recruiting
University of Kansas Hospital
Kansas City, Kansas · Recruiting
East Jefferson Hospital
Metairie, Louisiana · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
WA Uni School Of Med
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
New Jersey Urology LLC
Voorhees Township, New Jersey · Recruiting
Mount Sinai Hosp Med School
New York, New York · Recruiting
Associated Med Professionals of NY
Syracuse, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Central Ohio Urology Group
Gahanna, Ohio · Recruiting
Oregon Urology Institute
Springfield, Oregon · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Texas Oncology
Dallas, Texas · Recruiting
Urology San Antonio
San Antonio, Texas · Recruiting
Utah Intermountain Medical Center
Murray, Utah · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Onco Hemato Asso of SW Virginia
Roanoke, Virginia · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Medical College Of Wisconsin
Milwaukee, Wisconsin · Recruiting
Novartis Investigative Site
Darlinghurst, New South Wales, Australia · Recruiting
Novartis Investigative Site
Herston, Queensland, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.